2750233-50-0
2750233-50-0 structure
- Name: Antitumor agent-79
- Chemical Name: Antitumor agent-79
- CAS Number: 2750233-50-0
- Molecular Formula: C23H19ClN2O
- Molecular Weight: 374.86
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2022-11-17 07:24:00
- Modify Date: 2024-01-16 18:48:02
-
Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer[1].
| Name | Antitumor agent-79 |
|---|
| Description | Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.7 μM (Huh7), 1.4 μM (HepG2), 1.5 μM (SNU475), 7.9 μM (Hep3B), 2.4 μM (FOCUS), 5.2 μM (Hep40), 6.5 μM (PLC-PRF-5), 3.7 μM (Mahlavu), 0.9 μM (MCF7), 0.9 μM (MDA-MB231), 1.0 μM (MDA-MB468), 1.8 μM (SKBR3), 5.5 μM (ZR75), 7.6 μM (MCF10A)[1] |
| In Vitro | Antitumor agent-79 (0.15-40 μM; 72 h) shows in vitro growth inhibitory activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM[1]. Antitumor agent-79 (5 μM; 48 h) induces cell apoptosis by increasing the PARP cleavage[1]. Cell Cytotoxicity Assay[1] Cell Line: Huh7, HepG2, SNU475, Hep3B, FOCUS, Hep40, PLC-PRF-5, Mahlavu, MCF7, MDA-MB231. MDA-MB468, SKBR3, ZR75 and MCF10A cell lines Concentration: 0.15-40 μM Incubation Time: 72 hours Result: Time and dose-dependent showed cytotoxicity to hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7, 1.4, 1.5, 7.9, 2.4, 5.2, 6.5, 3.7, 0.9, 0.9, 1.0, 1.8, 5.5 and 7.6 μM for Huh7, HepG2, SNU475, Hep3B, FOCUS, Hep40, PLC-PRF-5, Mahlavu, MCF7, MDA-MB231, MDA-MB468, SKBR3, ZR75 and MCF10A cells, respectively. Western Blot Analysis[1] Cell Line: Mahlavu, Huh7, MCF-7 and MDA-MB-231 cancer cells Concentration: 5 μM Incubation Time: 48 hours Result: Increased the PARP cleavage in both breast cancer cells (MCF7 and MDA-MB-231) and hepatocellular carcinoma cells (Mahlavu). Apoptosis Analysis[1] Cell Line: Mahlavu, Huh7, MCF-7 and MDA-MB-231 cancer cells Concentration: 5 μM Incubation Time: 48 hours Result: Induced cell apoptosis of cancer cells. |
| In Vivo | Antitumor agent-79 (40 mg/kg; p.o. twice a week for 4 weeks) shows antitumor effects in mice xenograft models[1]. Animal Model: 6−8 weeks old male athymic nude mice with hepatocellular carcinoma (Mahlavu cells) and breast (MDA MB-231 cells) xenografts[1] Dosage: 40 mg/kg Administration: Oral gavage; 40 mg/kg; twice a week for 4 weeks Result: Significantly reduced the tumor volume following 4 weeks treatment with 40% reductions of tumor volumes in the Mahlavu xenografts. Resulted in about a 50% decreased in tumor volumes as compared to the control group in MDA-MB-231 xenografts. Showed well tolerated in vivo and neither significant bodyweight loss nor toxic effects or mortality were observed. |
| References |
| Molecular Formula | C23H19ClN2O |
|---|---|
| Molecular Weight | 374.86 |